University of Groningen
Access to innovative medicines in a middle-income country
Moye Holz, Daniela Denisse
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Moye Holz, D. D. (2019). Access to innovative medicines in a middle-income country: The case of Mexico
and cancer medicines. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Propositions
Access to Innovative Medicines in a Middle-Income Country
The Case of Mexico and Cancer Medicines
Daniela D. Moye Holz
1. Any price reduction achieved by Mexico’s pricing negotiating commission is a success. (this thesis) 2. Procuring medicines in health facilities at lower or higher prices than the nationally negotiated
procurement price undermines the pricing negotiating commission´s impact and performance.
(this thesis)
3. Over 80% of the Mexican population experiences barriers to innovative effective cancer medicines.
(this thesis)
4. Prescribing according to agreed clinical protocols leads to a better-designed, planned, and clear procurement process. (this thesis)
5. Outsourcing pharmacy services can improve efficiency in healthcare delivery. (this thesis)
6. Accreditation of a wider number of cancer facilities is imperative for universal health coverage in Mexico that should also include 2nd level and private healthcare facilities. (this thesis)
7. Health facilities in the public sector lack the necessary resources to procure the appropriate amounts of medicines, forcing some patients to rely on charity. (this thesis)
8. All medicines listed in the Mexican national formulary should be covered and be available in all health facilities in the public sector. (this thesis)
9. The experience with HIV provides an important lesson for non-communicable diseases: prevention and care are both essential and neither can be neglected. (Farmer et al. 2010)
10. Drug donations programs from pharmaceutical companies to developing countries can help strengthening health systems and improve access to medicines. (Mistry 2017)
11. “…If the pharmaceutical companies were better at adjusting their prices for different countries and different costumers, they could make their next fortune with what they already have”. (Rosling et al.
2018)
12. Many clinical trials are conducted on drugs that are simply close-copies of other products.
(Goldacre 2012)
13. “We should give more incentives to academics for publishing negative results; but [academic journals] should also give them more opportunity [to do so]”. (Goldacre 2012)
14. “…It’s a sign of strength to recognize when you don’t have the skills to do something – and reach out for help. Wanting to improve is not a sign of weakness”. (Sandberg 2017)
References
1. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: A call to action. Lancet. 2010;376(9747):1186-1193.
2. Mistry N. The role of drug donations in expanding access to medicines. Global Alliance for Patient Access. 2017. 3. Rosling H, Rosling Rönnlund A, Rosling O. Factfulness: Ten reasons we’re wrong about the world - and why
things are better than you think. 1st ed. London, UK: Hodder & Stoughton General Division; 2018. 4. Goldacre B. Bad pharma. How drug companies mislead doctors and harm patients. 1st ed. UK: Fourth Estate; 2012. 5. Sandberg S, Grant A. Option B. Facing adversity, building resilience, and finding joy. 1st ed. New York: Alfred
A. Knopf; 2017.
